All
Kiora Pharmaceuticals receives patent for KIO-104
Kiora Pharmaceuticals secures a patent for KIO-104, enhancing treatment options for ocular diseases and extending market exclusivity until 2043.
Evaluating ChatGPT-4o's ability to generate reliable retinal fundus images
OpenAI's ChatGPT-4o enhances ophthalmological image generation, producing realistic retinal photographs while highlighting the need for further research in training datasets.
Ocular Therapeutix announces upcoming conference presentations
Ocular Therapeutix to showcase its drug delivery solutions at upcoming ophthalmology conferences.
Role of mucormycosis infection on vision in diabetic patient
Mucormycosis emerges as a critical concern in diabetic patients with sudden vision loss, highlighting the need for prompt diagnosis and treatment.
Ocugen announces new SAB members and leadership changes
Retina roundup: July 14 to July 18
Catch up on this week's highlights in retina.
Moran Eye Center researcher plays role in AI use in eye care
AAVantgarde Bio receives IND clearance for AAVB-039
AAVB-039 advances gene therapy for Stargardt disease, aiming for innovative treatments for inherited retinal disorders.
FDA grants fast track designation to SAR446597
Sanofi's SAR446597 receives FDA fast track designation, offering a promising one-time gene therapy for geographic atrophy and reducing treatment frequency.
Survey data show trends for AMD and DME treatments and future prospects
The survey shows the evolving landscape of nAMD and DME treatments, highlighting physician preferences, payer influences, and the promise of gene therapy advancements.
Apellis announces 5 abstracts to be orally presented at the American Society of Retina Specialists (ASRS) annual meeting
Presentation highlights include 48-month data from the OAKS and DERBY trials as well as the GALE open-label extension.
Impending US trade tariffs may upend optical industry stability
New tariffs threaten the optical industry, prompting urgent reevaluation of sourcing strategies and pricing as deadlines approach for affected countries.
FDA grants Nanoscope rolling BLA submission of MCO-010
The completion of the full BLA submission is anticipated in early 2026 and is eligible for priority review under the program’s fast-track designation.
RetinalGeniX Technologies contracts Labcorp to support on DNA/RNA/GPS Pharmaco-Genetic Mapping platform
RetinalGeniX partners with Labcorp to enhance genetic testing and retinal imaging, aiming for early disease detection and improved patient care.
Retina roundup: July 7 to July 11
Study links cannabis use to lower risk of proliferative vitreoretinopathy after retinal detachment repair
A recent study reveals cannabis use may lower the risk of proliferative vitreoretinopathy after retinal detachment repair, suggesting potential therapeutic benefits.
Comparing vorolanib intravitreal insert with aflibercept in DME treatment
EYP-1901 shows promising results in reducing treatment burden for diabetic macular edema, offering sustained improvements in vision and safety.
Enrollment complete for Beacon Therapeutics' phase 2/3 VISTA trial
The VISTA trial is evaluating and comparing 2 dose levels of laru-zova with an untreated control group for the treatment of X-linked retinitis pigmentosa (XLRP).
FDA agrees to expand Atsena's gene therapy trial for XLRS treatment
Atsena Therapeutics expands its ATSN-201 trial for X-linked retinoschisis, a step toward the first gene therapy treatment.
Reducing site burden and expanding research capacity with AI
How artificial intelligence could enhance clinical trials.
Exposure to pesticides and increased risk of AMD
A new study links urinary metabolites from organophosphorus pesticides to increased age-related macular degeneration risk.
A review of the DAVIO 2 phase 2 trial results
A hope for reducing treatment burden for wet age-related macular degeneration with a sustained-release vorolanib intravitreal insert
Health Canada approves aflibercept biosimilar Aflivu
Health Canada approves Aflivu, a biosimilar for retinal diseases, enhancing treatment options and affordability for Canadian patients.
Alcon to acquire LumiThera and its photobiomodulation device for the treatment of dry AMD
LumiThera’s PBM is the only device that has demonstrated meaningful vision improvement compared to baseline for people living with early to intermediate dry AMD.
Phase 3 PHOENIX trial for oral GA treatment completes enrollment
Belite Bio completes enrollment in the pivotal PHOENIX trial, advancing tinlarebant's potential to treat geographic atrophy.
Multiple intravitreal injections and their effect on the optic nerve head in patients with CRVO
Research from the iMIND lab at Duke University.
THULITE phase II study evaluates BI 1815368
Boehringer Ingelheim initiates THULITE study, exploring an oral treatment for diabetic macular edema, aimed to improve patient care and convenience.
Highlights from ARVO 2025
Retinal imaging and the future of early Alzheimer diagnosis.
Intravitreal implant shows potential for treating the root causes of glaucoma and diabetic retinopathy
New clinical trials reveal PER-001 as a new treatment for glaucoma and diabetic retinopathy, showing significant vision improvements and safety.
Retina roundup: June 30 to July 4
